Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2013 - 2026)
Palvella Therapeutics (PVLA) reported Net Income towards Common Stockholders of -$15.8 million for Q1 2026, down 92.63% year-over-year from -$214.0 million in Q1 2025, and down 154.25% quarter-over-quarter from $29.1 million in Q4 2025.
Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$15.8 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$15.8 million, down 92.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.5 million (up 67.15% YoY), and the FY2025 annual result was $64000.0, up 100.37% from the prior year.
- Net Income towards Common Stockholders retreated to -$15.8 million in Q1 2026 per PVLA's latest filing, from $29.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $29.1 million in Q4 2025 and troughed at -$15.8 million in Q1 2026.
- A 5-year average of -$4.7 million and a median of -$7.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 271.01% in 2024, then jumped 962.72% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.9 million in 2022, then soared by 212.23% to $13.4 million in 2023, then tumbled by 125.17% to -$3.4 million in 2024, then jumped by 962.72% to $29.1 million in 2025, then plunged by 154.25% to -$15.8 million in 2026.
- Business Quant data shows PVLA's Net Income towards Common Stockholders at -$15.8 million in Q1 2026, $29.1 million in Q4 2025, and -$11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Palvella Therapeutics | 1.42 Bn | 1.16 Bn | - | -15.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.77 Mn |
| Dec 31, 2025 | 29.07 Mn |
| Sep 30, 2025 | -11.35 Mn |
| Jun 30, 2025 | -9.47 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -6.97 Mn |
| Jun 30, 2024 | -4.37 Mn |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | -11.26 Mn |
| Jun 30, 2023 | 2.55 Mn |
| Mar 31, 2023 | -15.15 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -12.20 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.01 Mn |
| Sep 30, 2021 | -19.01 Mn |
| Jun 30, 2021 | -16.76 Mn |
| Mar 31, 2021 | -5.06 Mn |